Date: 2015-06-08
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the American Diabetes Association Scientific Sessions in Boston, Massachusetts
Company: Amarin (Ireland)
Product: eicosapentaenoic acid
Action mechanism:
Disease:
Therapeutic area: Cardiovascular diseases - Metabolic diseases
Country:
Trial details:
Latest
news: * On June 11, 2015, Amarin Corporation announced the presentation of findings from a new in vitro study at the National Lipid Association Scientific Sessions being held June 11-14 in Chicago. The study of the inhibitory effect of eicosapentaenoic acid (EPA) on the formation of cholesterol crystalline domains in model biological membranes subjected to high cholesterol levels (to simulate atherosclerotic-like conditions) indicated a level of reduction with EPA that was not reproduced with other triglyceride-lowering agents tested. The poster, titled \"Eicosapentaenoic Acid (EPA), But Not Other TG-Lowering Agents, Reduces Cholesterol Domain Levels in Atherosclerotic-Like Model Membranes,\" will be presented at the author Q&A session scheduled for June 13, 2015 from 11:20 a.m.-12:20 p.m. CDT. \"This study was conducted in vitro using model biological membranes under conditions of hypercholesterolemia,\" commented Preston Mason, Ph.D., of Brigham and Women\'s Hospital and the study\'s lead investigator. \"The purpose of the study was to examine whether EPA, under atherosclerotic-like conditions, can reduce the formation of cholesterol crystalline domains. Our research team found that EPA reduced cholesterol crystalline domain levels in cholesterol-enriched model membranes by 65% (p < 0.05) as compared to vehicle-treated (ethanol) controls.\" Additional studies are needed to determine if the effects of EPA shown in this study would have clinically meaningful benefit in the human body. This poster will be presented by Dr. R. Preston Mason, PhD, of Brigham and Women\'s Hospital. Dr. Mason is also the President and Founder of Elucida Research. * On June 8, 2015, Amarin Corporation announced the presentation of findings from a new in vitro study at a peer-reviewed poster session at the American Diabetes Association Scientific Sessions in Boston, Massachusetts. The poster, titled \"Eicosapentaenoic Acid (EPA) Reduces Glucose-induced Small Dense Low-Density Lipoprotein Oxidation In Vitro in a Manner Distinct from Other Triglyceride-Lowering Agents and Vitamin E,\" presents data that shows exposure to eicosapentaenoic acid (EPA), an omega-3 fatty acid, inhibited glucose-induced oxidation of small dense LDL. This study examined the effects of EPA and other triglyceride-lowering agents on human sdLDL oxidation following exposure in vitro to hyperglycemic conditions. Exposure to hyperglycemic conditions resulted in a 55% increase in human sdLDL oxidation as compared to non-glucose-treated controls as measured by a marker of oxidation (malondialdehyde (MDA)). EPA inhibited this glucose-induced sdLDL oxidation in a dose-dependent fashion and, at the highest concentration tested (10.0 µM), EPA inhibited sdLDL oxidation by 94% compared to vehicle treated (ethanol) control. Additional studies are needed to determine if the effects of EPA shown in this study would have clinically meaningful benefit in the human body. This poster was presented by Dr. R. Preston Mason, PhD, of Brigham and Women\'s Hospital. Dr. Mason is also the President and Founder of Elucida Research.
